	Item No	Recommendation
Title and abstract	1	(x) Indicate the study's design with a commonly used term in the title or the abstract
		(b) Provide in the abstract an informative and balanced summary of what was done
		and what was found Page 3
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Pag
Objectives	3	State specific objectives, including any prespecified hypotheses Page 7
Methods		
Study design	4	Prosent key elements of study design early in the paper Page 7–9
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,
	3	exposure, follow-up, and data collection Page 7-8
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of
	O	selection of participants. Describe methods of follow-up
		Case-control study—Give the eligibility criteria, and the sources and methods of
		case ascertainment and control selection. Give the rationale for the choice of cases
		and controls
		Cross-sectional study—Give the eligibility criteria, and the sources and methods of
		selection of participants Page 7–8
		(b) Cohort study—For matched studies, give matching criteria and number of
		exposed and unexposed
		Case-control study—For matched studies, give matching criteria and the number of
		controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
variables	,	modifiers. Give diagnostic criteria, if applicable Page 8
Data sources/	8*	For each variable of interest, give sources of data and details of methods of
measurement		assessment (measurement). Describe comparability of assessment methods if there
		is more than one group Page 7-9
Bias	9	Describe any efforts to address potential sources of bias / Page 9–10
Study size	10	Explain how the study size was arrived at \ Page 7-8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,
		describe which groupings were chosen and why Page 9-10
Statistical methods	12	Describe all statistical methods, including those used to control for confounding Page
		(b) Describe any methods used to examine subgroups and interactions Page 9-10
		(c) Explain how missing data were addressed Page 9-10
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed
		Case-control study—If applicable, explain how matching of cases and controls was
		addressed
		Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy Page 9
		(e) Describe any sensitivity analyses $\sqrt{\text{Page }9-10}$
Continued on next page		

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page 10	
		(b) Give reasons for non-participation at each stage Page 10	
		(c) Consider use of a flow diagram	
Descriptive	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information	
data		on exposures and potential confounders Page 10	
		(b) Indicate number of participants with missing data for each variable of interest Page 10	
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time	
		Case-control study—Report numbers in each exposure category, or summary measures of	
		exposure	
		Cross-sectional study—Report numbers of outcome events or summary measures Page 10	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their	
		precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and	
		why they were included Page 10-12	
		(b) Keport category boundaries when continuous variables were categorized Page 10-12	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Page 10–12	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Page 10-11	
Discussion			
Key results	18	Summarise key results with reference to study objectives \ Page 12 and Page 15-16	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.	
		Discuss both direction and magnitude of any potential bias \ Page 16	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity	
		of analyses, results from similar studies, and other relevant evidence Page 12-15	
Generalisability	21	Discuss the generalisability (external validity) of the study results Page 12-15	
Other information	on	<u> </u>	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable,	
		for the original study on which the present article is based	

^{*}Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.